Demarcating Therapeutic Interventions in IBS

---

Review Article

Author Details : Sunil Chaudhry*

Volume : 8, Issue : 2, Year : 2020

Article Page : 65-75

https://doi.org/10.18231/j.jpbs.2020.010

Suggest article by email

Get Permission

---

Abstract

Irritable bowel syndrome (IBS), also referred to as mucus colitis, nervous colon, and spastic colitis is a long-term chronic gastrointestinal disorder that can cause continuous discomfort. IBS has a significant impact on patients’ quality of life due to physical suffering, psychological co-morbidity, social disability and economic non-productivity. It is more common in females and in lower socioeconomic groups. The diagnosis declines with age (with most affected individuals younger than age 50) The diagnosis of IBS relies on a symptom-based classification system known as Rome criteria. The low FODMAP diet is recommended for patients with digestive disorders like Irritable Bowel Syndrome. Current therapy of IBS focuses on the major symptoms experienced by patients. The novel approach in the treatment of IBS is based either on targeting specific receptors in the gastrointestinal tract that are known to be involved in the pathogenesis of the disease.

Keywords: Irritable bowel syndrome (IBS), Bloating, Rome Criteria, FODMAP, 5HTagonists and antogonists.

How to cite : Chaudhry S , Demarcating Therapeutic Interventions in IBS. J Pharm Biol Sci 2020;8(2):65-75

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.